This content is current only at the time of printing. This document was printed on 2 July 2020. A current copy is located at https://apvma.gov.au/node/11411
You are here
Proposed variation to registration of Draxxin Injectable Solution containing the approved active constituent tulathromycin
This consultation closed on 16 July 2013.
The APVMA is considering an application to vary the use of the existing registered product Draxxin Injectable Solution containing the approved active constituent tulathromycin (APVMA Product number 60018).
We invite written comment from 18 June 2013 to 16 July 2013 on the trade implications of this registration proposal.
The APVMA is able to consider comments relating to the legislative grounds for the assessment, which are the trade implications of the use of the product. The Trade Advice Notice provides a summary of the APVMA's residue and trade assessment.
Email your written submissions to email@example.com. We prefer emailed submissions. However, hardcopy submissions (or files on digital media) can be sent to:
Contact Officer, Veterinary Medicines
Veterinary Medicines Program
Australian Pesticides and Veterinary Medicines Authority
PO Box 6182
KINGSTON ACT 2604
For enquiries, please call: +61 2 6210 4789